Results 111 to 120 of about 3,893,535 (160)

Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? [PDF]

Lancet Reg Health Eur
Panzuto F, Cives M, Strosberg J.
europepmc   +1 more source

Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer. [PDF]

Pharmaceutics
Zavvar TS, Santo G, Gruber L, Kronthaler A, Hagenbuchner J, Skvortsova I, Piro I, Steiger K, Martinovic V, Minasch D, Löffler-Ragg J, di Santo G, Virgolini IJ, von Guggenberg E.   +13 more
europepmc   +1 more source

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial. [PDF]

Front Endocrinol (Lausanne)
Kolodziej M, Opalinska M, Mikolajczak R, Hubalewska-Dydejczyk A, Dedecjus M, Kowalska A, Saracyn M, Garnuszek P, Cieszykowska I, Januszkiewicz-Caulier J, Dlugosinska J, Durma AD, Jozwik-Plebanek K, Mroz A, Janiak K, Gasior-Perczak D, Trofimiuk-Muldner M, Sowa-Staszczak A, Braziewicz J, Lenda-Tracz W, Kacperski K, Budzynska A, Kubik A, Pastusiak P, Chalewska W, Borkowska A, Cegla P, Walecka-Mazur A, Szczodry A, Kaminski G.   +29 more
europepmc   +1 more source

Machine Learning Uncovers Novel Predictors of Peptide Receptor Radionuclide Therapy Eligibility in Neuroendocrine Neoplasms. [PDF]

Cancers (Basel)
Sipka G, Farkas I, Bakos A, Maráz A, Mikó ZS, Czékus T, Bukva M, Urbán S, Pávics L, Besenyi Z.   +9 more
europepmc   +1 more source

Recommendations for selection, treatment, and follow-up in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors: a Delphi consensus from the Galician Multidisciplinary Group on Neuroendocrine and Endocrine Tumors (GGNET). [PDF]

Clin Transl Oncol
Martinez-Lago N, Cabezas Agricola JM, Anido Herranz U, Nogareda Seoane Z, Cousillas Castiñeiras A, Varela Ponte R, Fernández Catalina P, Abou Jokh Casas E, de Matías Leralta JM, Pubul Nuñez V.   +9 more
europepmc   +1 more source

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. [PDF]

Pharmaceuticals (Basel)
Leupe H, Cauwenbergh M, Cleeren F, Dekervel J, Verslype C, Deroose CM.   +5 more
europepmc   +1 more source

Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study. [PDF]

Ann Nucl Med
Kobayashi N, Ono H, Okubo N, Akahoshi K, Kudo A, Ban D, Ichikawa Y.   +6 more
europepmc   +1 more source

IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. [PDF]

Int J Mol Sci
Vuleta Nedic K, Gajovic N, Jovanovic I, Jurisevic M, Jovanovic M, Jakovljević S, Popovic B, Djordjevic J, Ignjatovic V, Vukomanovic V.   +9 more
europepmc   +1 more source

Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors. [PDF]

J Neuroendocrinol
Santo G, di Santo G, Cicone F, Virgolini I.   +3 more
europepmc   +1 more source

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [¹⁸F]FDG-positive metastatic neuroendocrine tumors. [PDF]

Eur J Nucl Med Mol Imaging
di Santo G, Santo G, Wirth L, Kronthaler A, Gastl G, Djanani A, Virgolini IJ.   +6 more
europepmc   +1 more source